Scholarlink

Purpose <p>To evaluate whether peri-induction intravenous aprepitant 32mg/4.4ml improves the complete response&#xa0;(CR) to postoperative nausea and vomiting&#xa0;(PONV) within 24 h after surgery, as well as the 0–48 h net clinical effect, safety, and pharmacokinetic outcomes, in Chinese adults at moderate to high risk of PONV under a standardized rescue protocol.</p> Methods <p>This multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in 30 hospitals&#xa0;in China. A total of 412 patients scheduled for abdominal or pelvic surgery with an Apfel simplified risk score ≥ 2 were randomized 1:1 to the aprepitant group (<i>n</i> = 206) or placebo (<i>n</i> = 206). Patients in the aprepitant group received intravenous aprepitant 32 mg before anesthesia induction, while those in the control group received placebo. Rescue antiemetics were administered only for clinically significant postoperative symptoms. The primary endpoint was CR within 24 h after surgery, defined as no vomiting or retching and no use of rescue antiemetic therapy during the first 24 postoperative hours. Secondary endpoints included time to first emesis within 48 h, incidence of moderate-to-severe nausea within 24 h, and rescue antiemetic use within 24 h after surgery. A pharmacokinetic substudy (<i>n</i> = 28) measured plasma aprepitant concentration at 0 and 2&#xa0;min, 5&#xa0;min, 15&#xa0;min, 1&#xa0;h, 3&#xa0;h, 6&#xa0;h, 24&#xa0;h and 48&#xa0;h after completion of administration. Adverse events were recorded to assess safety.</p> Results <p>Aprepitant significantly increased the rate of CR within 24 h compared with placebo (81.4% vs. 39.0%; <i>P</i> &lt; 0.001). Vomiting within 48 h occurred less frequently in the aprepitant group than in the control group (16.7% vs. 62.0%; <i>P</i> &lt; 0.001), and time to first emesis within 48&#xa0;h was significantly delayed with aprepitant (log-rank <i>P</i> &lt; 0.001). The proportion&#xa0;of patients with no emesis was higher in the aprepitant group at both 24&#xa0;h (84.8% vs. 40.0%; weighted risk difference, 45.07% [95% CI, 36.90%–53.24%]) and 48&#xa0;h (83.3% vs. 38.0%; weighted risk difference, 45.55% [95% CI, 37.29%–53.81%]). Moderate-to-severe nausea within 24 h was reduced&#xa0;with aprepitant (16.7% vs. 33.2%; <i>P</i> &lt; 0.001), as was rescue antiemetic use within 24 h (8.3% vs. 22.0%; <i>P</i> &lt; 0.001). In the pharmacokinetic substudy, the mean (SD) <i>C</i><sub>max</sub> was 4997.95 (1226.44) ng/mL, the median (range) <i>T</i><sub>max</sub> was 0.035 (0.031–0.076), and the&#xa0;mean (SD) half-life (<i>T</i><sub>1/2</sub>) was 9.08 (2.17). Adverse reaction profiles were similar between groups.</p> Conclusions <p>Peri-induction intravenous aprepitant 32&#xa0;mg substantially improved the 24 h CR rate in Chinese adults at moderate to high risk of PONV undergoing abdominal or pelvic surgery. This benefit was accompanied by delayed time to first emesis, reduced moderate-to-severe nausea, and lower rescue antiemetic use, with a safety profile comparable to placebo.</p> Clinical trial registration <p>Chinese Clinical Trial Registry, ChiCTR2400082488. Registered on 29 March 2024, <a href="https://www.chictr.org.cn/showproj.html?proj=224587">https://www.chictr.org.cn/showproj.html?proj=224587</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intravenous aprepitant for prevention of postoperative nausea and vomiting in adults at moderate-to-high risk in China: a multicenter, randomized, double-blind, placebo-controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Shichao Luo,
  • Xiangqin Teng,
  • YingYong Zhou,
  • Qinghong Mao,
  • Qingmei Zhang,
  • Hong Luo,
  • Liang Chen,
  • Juan Wang,
  • Hongmei Zhou,
  • Jun Jing,
  • Chuping Ye,
  • Canlin Sun,
  • Rui Zhan,
  • Jinghua Ren,
  • Chun Chen,
  • Ping Qiang,
  • Mingzhi Zheng,
  • Wanyou Yu,
  • Saiying Wang,
  • Kaiming Duan

摘要

Purpose

To evaluate whether peri-induction intravenous aprepitant 32mg/4.4ml improves the complete response (CR) to postoperative nausea and vomiting (PONV) within 24 h after surgery, as well as the 0–48 h net clinical effect, safety, and pharmacokinetic outcomes, in Chinese adults at moderate to high risk of PONV under a standardized rescue protocol.

Methods

This multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in 30 hospitals in China. A total of 412 patients scheduled for abdominal or pelvic surgery with an Apfel simplified risk score ≥ 2 were randomized 1:1 to the aprepitant group (n = 206) or placebo (n = 206). Patients in the aprepitant group received intravenous aprepitant 32 mg before anesthesia induction, while those in the control group received placebo. Rescue antiemetics were administered only for clinically significant postoperative symptoms. The primary endpoint was CR within 24 h after surgery, defined as no vomiting or retching and no use of rescue antiemetic therapy during the first 24 postoperative hours. Secondary endpoints included time to first emesis within 48 h, incidence of moderate-to-severe nausea within 24 h, and rescue antiemetic use within 24 h after surgery. A pharmacokinetic substudy (n = 28) measured plasma aprepitant concentration at 0 and 2 min, 5 min, 15 min, 1 h, 3 h, 6 h, 24 h and 48 h after completion of administration. Adverse events were recorded to assess safety.

Results

Aprepitant significantly increased the rate of CR within 24 h compared with placebo (81.4% vs. 39.0%; P < 0.001). Vomiting within 48 h occurred less frequently in the aprepitant group than in the control group (16.7% vs. 62.0%; P < 0.001), and time to first emesis within 48 h was significantly delayed with aprepitant (log-rank P < 0.001). The proportion of patients with no emesis was higher in the aprepitant group at both 24 h (84.8% vs. 40.0%; weighted risk difference, 45.07% [95% CI, 36.90%–53.24%]) and 48 h (83.3% vs. 38.0%; weighted risk difference, 45.55% [95% CI, 37.29%–53.81%]). Moderate-to-severe nausea within 24 h was reduced with aprepitant (16.7% vs. 33.2%; P < 0.001), as was rescue antiemetic use within 24 h (8.3% vs. 22.0%; P < 0.001). In the pharmacokinetic substudy, the mean (SD) Cmax was 4997.95 (1226.44) ng/mL, the median (range) Tmax was 0.035 (0.031–0.076), and the mean (SD) half-life (T1/2) was 9.08 (2.17). Adverse reaction profiles were similar between groups.

Conclusions

Peri-induction intravenous aprepitant 32 mg substantially improved the 24 h CR rate in Chinese adults at moderate to high risk of PONV undergoing abdominal or pelvic surgery. This benefit was accompanied by delayed time to first emesis, reduced moderate-to-severe nausea, and lower rescue antiemetic use, with a safety profile comparable to placebo.

Clinical trial registration

Chinese Clinical Trial Registry, ChiCTR2400082488. Registered on 29 March 2024, https://www.chictr.org.cn/showproj.html?proj=224587.